journal
MENU ▼
Read by QxMD icon Read
search

Journal of Thrombosis and Haemostasis: JTH

journal
https://www.readbyqxmd.com/read/28222250/long-term-treatment-of-cancer-associated-thrombosis-the-choice-of-the-optimal-anticoagulant
#1
REVIEW
I Elalamy, I Mahé, W Ageno, G Meyer
Patients with cancer associated thrombosis (CAT) carry a higher risk of recurrence, bleeding and mortality as compared to non-cancer patients. The specific profile of cancer patients combining frequent co-morbidities, the use of anti-tumoral therapies and the cancer progression itself represent a major therapeutic challenge for choosing a long-term anticoagulant treatment. This review discusses the practical basis of that choice among available drugs for the long-term antithrombotic strategy linked to their pharmacology, mechanism of action, evidence of clinical benefits, advantages and limitations in such a complex clinical context...
February 21, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28213951/what-the-neighbors-say
#2
EDITORIAL
(no author information available yet)
No abstract text is available yet for this article.
February 18, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28211169/a-first-in-human-study-of-ds-1040-an-inhibitor-of-the-activated-form-of-thrombin-activatable-fibrinolysis-inhibitor-in-healthy-subjects
#3
Jin Zhou, Jarema Kochan, Ophelia Yin, Vance Warren, Cynthia Zamora, George Atiee, Joseph Pav, Yasushi Orihashi, Vijay Vashi, Victor Dishy
BACKGROUND: Current treatments for acute ischemic stroke and venous thromboembolism, such as recombinant tissue plasminogen activator and thrombectomy, are limited by a narrow time window and the risk of bleeding. DS-1040 is a novel low-molecular weight compound inhibiting the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa), developed as a fibrinolysis enhancer for treatment of thromboembolic diseases. OBJECTIVES: This first-in-human, randomized, placebo-controlled, three-part, phase 1 study was conducted to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of DS-1040 in healthy subjects...
February 17, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28211163/new-functional-assays-to-selectively-quantify-the-apc-and-tfpi-cofactor-activities-of-protein-s-in-plasma
#4
N Alshaikh, J Rosing, M C L G D Thomassen, E Castoldi, P Simioni, T M Hackeng
BACKGROUND: Protein S plays an important role in the down-regulation of coagulation as cofactor for activated protein C (APC) and tissue factor pathway inhibitor (TFPI). AIM: To develop functional assays to quantify the APC- and TFPI-cofactor activities of protein S in plasma. METHODS: APC- and TFPI-cofactor activities of protein S in plasma were measured using calibrated automated thrombography in protein S-depleted plasma supplemented with a small amount of sample plasma either in the presence of anti-TFPI antibodies and APC (APC-cofactor activity) or at excess full-length TFPI without APC (TFPI-cofactor activity)...
February 17, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28211264/genetics-diagnosis-and-clinical-features-of-congenital-hypodysfibrinogenaemia-a-systematic-literature-review-and-report-of-a-novel-mutation
#5
A Casini, T Brungs, C Lavenu-Bombled, R Vilar, M Neerman-Arbez, P de Moerloose
BACKGROUND: Hypodysfibrinogenaemia is a rare disease characterised by decreased levels of a dysfunctional fibrinogen. It shares features with both hypo- and dysfibrinogenaemia, although with specific molecular patterns and clinical phenotypes. OBJECTIVES: To better define the genetics, the diagnosis and the clinical features of hypodysfibrinogenaemia. PATIENTS/METHODS: A systematic literature search led to 167 records. After removal of duplicates, abstract screening and full-text reviewing, 56 molecular and/or clinical studies were analysed, including a novel FGB missense mutation in a woman with a mild bleeding phenotype...
February 16, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28182327/microangiopathic-hemolytic-anemia-due-to-adamts-13-loss-in-idiopathic-systemic-capillary-leak-syndrome-reply
#6
Daniel C Moreira, Jorge Di Paola
We sincerely appreciate Dr Thachil's letter, which provides further insight into the case we recently published, in which ADAMTS-13 was likely lost in third-space fluid in a patient with idiopathic systemic capillary leak syndrome (SCLS) and that this loss was proposed as a novel mechanism for microangiopathic hemolytic anemia (MAHA) [1]. As mentioned in the original publication, identifying high levels of ADAMTS-13 in the transudate fluid would have proven the proposed mechanism, but unfortunately a sample of the transudate fluid was not available...
February 9, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28182324/clumping-factor-a-von-willebrand-factor-binding-protein-and-von-willebrand-factor-anchor-staphylococcus-aureus-to-the-vessel-wall
#7
J Claes, L Liesenborghs, M Peetermans, T R Veloso, D Missiakas, O Schneewind, S Mancini, J M Entenza, M F Hoylaerts, R Heying, P Verhamme, T Vanassche
OBJECTIVE: When establishing endovascular infections, Staphylococcus aureus (S. aureus) overcomes shear forces of flowing blood by binding to von Willebrand factor (VWF). Staphylococcal VWF-binding protein (vWbp) interacts with VWF, but it is unknown how this secreted protein binds to the bacterial cell wall. We hypothesized that vWbp interacts with a staphylococcal surface protein, mediating the adhesion of S. aureus to VWF and vascular endothelium under shear stress. METHODS: We studied the binding of S...
February 9, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28182323/ibrutinib-associated-bleeding-pathogenesis-management-and-risk-reduction-strategies
#8
REVIEW
Joseph J Shatzel, Sven R Olson, Derrick L Tao, Owen J T McCarty, Alexey V Danilov, Thomas G DeLoughery
Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) that has proven to be an effective therapeutic agent for multiple B-cell mediated lymphoproliferative disorders. Ibrutinib, however, carries an increased bleeding risk compared to standard chemotherapy. Bleeding events range from minor mucocutaneous bleeding to life-threatening hemorrhage, due in large part to the effects of ibrutinib on several distinct platelet signaling pathways. There is currently minimal data to guide clinicians regarding the use of ibrutinib in patients at high risk for bleeding or on anticoagulant or antiplatelet therapy...
February 9, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28166609/modulating-immunogenicity-of-factor-ix-by-fusion-to-an-immunoglobulin-fc-domain-a-study-using-hemophilia-b-mouse-model
#9
Ditza Levin, H A Daniel Lagassé, Erin Burch, Scott Strome, Siyuan Tan, Haiyan Jiang, Zuben E Sauna, Basil Golding
BACKGROUND: Fc-fusion is a platform technology used to increase the circulating half-life of protein and peptide therapeutics. However, there are potential immunological consequences with this approach, such as changes in the molecule's immunogenicity as well as possible interactions with a repertoire of Fc-receptors (FcR) which can modulate immune responses. OBJECTIVES/METHODS: Using a mouse hemophilia B (HB) model, we compared the immune responses to infusions of recombinant human Factor IX (hFIX) and hFIX fused to mouse IgG2a-Fc (hFIX-mFc)...
February 6, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28166608/safety-efficacy-and-pharmacokinetics-of-rviii-singlechain-in-children-with-severe-hemophilia-a-sesults-of-a-multicenter-clinical-trial
#10
Oleksandra Stasyshyn, Claudia Djambas Khayat, Genadi Iosava, Jeannie Ong, Faraizah Abdul Karim, Kathelijn Fischer, Alex Veldman, Nicole Blackman, Katie St Ledger, Ingrid Pabinger
BACKGROUND: rVIII-SingleChain, is a novel B-domain truncated recombinant Factor VIII (rFVIII) comprised of covalently bonded FVIII heavy and light chains, demonstrating a high binding affinity to von Willebrand Factor. OBJECTIVES: This Phase III study investigated the safety, efficacy and pharmacokinetics of rVIII-SingleChain in previously treated pediatric patients <12 years of age with severe hemophilia A. PATIENTS/METHODS: Patients could be assigned to prophylaxis or on-demand therapy by the investigator...
February 6, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28166607/recombinant-fibrinogen-reveals-the-differential-roles-of-%C3%AE-and-%C3%AE-chain-cross-linking-and-molecular-heterogeneity-in-fibrin-clot-strain-stiffening
#11
I K Piechocka, N A Kurniawan, J Grimbergen, J Koopman, G H Koenderink
BACKGROUND: Fibrin plays a crucial role in haemostasis and wound healing by forming strain-stiffening fibrous networks that reinforce blood clots. The molecular origin of fibrin's strain-stiffening behavior remains poorly understood, primarily because plasma fibrinogen is a complex mixture of heterogeneous molecular variants and is often contaminated by plasma factors that affect clot properties. OBJECTIVES AND METHODS: To facilitate mechanistic dissection of fibrin nonlinear elasticity, we produced a homogeneous recombinant fibrinogen corresponding to the main variant in human plasma, termed rFib610...
February 6, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28166605/d-dimer-at-venous-thrombosis-diagnosis-is-associated-with-risk-of-recurrence
#12
Esben Bjøri, Håkon S Johnsen, John-Bjarne Hansen, Sigrid K Braekkan
BACKGROUND: Venous thromboembolism (VTE) is a common disease with a high recurrence rate. D-dimer measured after cessation of anticoagulant therapy predicts recurrence, and is used to decide on treatment prolongation. However, whether d-dimer measured at first VTE diagnosis can be used to assess recurrence-risk is unknown. AIMS: To investigate the association between d-dimer, measured at first VTE diagnosis, and risk of recurrent VTE. METHODS: Information on clinical risk factors and laboratory markers were collected in 454 cancer-free patients with a first VTE...
February 6, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28164424/filaggrin-loss-of-function-mutations-as-risk-factors-for-ischemic-stroke-in-the-general-population
#13
Anette Varbo, Børge G Nordestgaard, Marianne Benn
BACKGROUND: Heritability studies have shown a considerable genetic component to ischemic stroke risk; however, much is unknown as to which genes are responsible. Also, previous studies have found an association between atopic dermatitis and increased ischemic stroke risk. OBJECTIVE: To test the hypothesis that FLG loss-of-function mutations, known to be associated with atopic dermatitis, were also associated with ischemic stroke. METHODS: 97,174 individuals, with 3,597 cases of ischemic stroke, from the Copenhagen General Population Study, the Copenhagen City Heart Study, and the Copenhagen Carotid Stroke Study were genotyped for the two most common filaggrin mutations, FLG R501X and FLG 2282del4...
February 6, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28158924/what-the-neighbours-say
#14
EDITORIAL
(no author information available yet)
No abstract text is available yet for this article.
February 3, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28150907/venous-thromboembolism-following-l-asparaginase-treatment-for-lymphoid-malignancies-in-korea
#15
J H Lee, J Lee, H-Y Yhim, D Oh, S-M Bang
BACKGROUND: L-asparaginase (L-asp) associated venous thromboembolism (VTE) is a serious adverse complication associated with acute lymphoblastic leukemia (ALL) and lymphoma treatment. The incidence rate of L-asp related VTE in Asian cancer patients is not well known. METHODS: We performed a population-based study between 2009 and 2013 using claim databases including both diagnostic and medication codes, such as anti-cancer treatment with L-asp, and VTE diagnoses from the starting date until 3 months after cessation of L-asp...
February 2, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28135786/the-effect-of-correcting-verifynow-p2y12-assay-results-for-hematocrit-in-patients-undergoing-percutaneous-coronary-interventions
#16
P W A Janssen, T O Bergmeijer, T C Godschalk, T T D Le, N J Breet, J C Kelder, C M Hackeng, J M Ten Berg
BACKGROUND: High on-treatment platelet reactivity is predictive for the occurrence of atherothrombotic events following percutaneous coronary interventions (PCI). A low hematocrit (HCT) value is associated with higher platelet reactivity values expressed in P2Y12 reaction units (PRU) as measured with the VerifyNow P2Y12 assay. However, it is suggested that this is only an in vitro phenomenon. OBJECTIVE: To determine whether adjusting PRU for HCT improves the predictive value for thrombotic events following PCI...
January 30, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28135054/integrated-analysis-of-genetic-variation-and-gene-expression-reveals-novel-variant-for-increased-warfarin-dose-requirement-in-african-americans
#17
Wenndy Hernandez, Eric R Gamazon, Keston Aquino-Michaels, Erin Smithberger, Travis J O'Brien, Arthur F Harralson, Matthew Tuck, April Barbour, Larisa H Cavallari, Minoli A Perera
BACKGROUND: Warfarin is commonly used to control and prevent thromboembolic disorders. However, due to warfarin's complex dose-requirement relationship, safe and effective use is challenging. Pharmacogenomics-guided warfarin dosing algorithms that include the well-established VKORC1 and CYP2C9 polymorphisms explain only a small proportion of inter-individual variability in African Americans (AAs). OBJECTIVES: We aimed to assess whether transcriptomic analyses could be used to identify regulatory variants associated with warfarin dose response in AAs...
January 30, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28135041/inflammatory-bowel-disease-and-venous-thromboembolism-during-pregnancy-and-the-postpartum-period
#18
Anette Tarp Hansen, Rune Erichsen, Erzsébet Horváth-Puhó, Henrik Toft Sørensen
BACKGROUND: The incidence of inflammatory bowel disease (IBD) increases, thus becoming more common also among pregnant women. IBD is a risk factor for venous thromboembolism (VTE), but it is not clear whether IBD infers an excess risk of VTE during pregnancy and the postpartum period. METHODS: A nationwide population-based cohort study of all deliveries during 1980-2013 in Denmark, using data from two nationwide health registries: the Danish National Patient Registry and the Medical Birth Registry...
January 30, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28135040/lipid-levels-and-risk-of-recurrent-venous-thrombosis-results-from-the-mega-follow-up-study
#19
V M Morelli, W M Lijfering, F R Rosendaal, S C Cannegieter
BACKGROUND: Knowledge of risk factors for recurrent venous thrombosis may guide decisions on duration of anticoagulation. The association between lipid levels and first venous thrombosis has been studied extensively. However, data on the role of lipids in the risk of recurrence are scarce. OBJECTIVE: To assess the association between lipid levels and recurrent venous thrombosis. PATIENTS/METHODS: Patients with a first venous thrombosis were included from the MEGA study...
January 30, 2017: Journal of Thrombosis and Haemostasis: JTH
https://www.readbyqxmd.com/read/28135035/fibrinolysis-inhibitors-in-plaque-stability-a-morphological-association-pai-1-and-tafi-in-advanced-carotid-plaque
#20
A-C Jönsson Rylander, A Lindgren, J Deinum, G M L Bergström, G Böttcher, I Kalies, K Wåhlander
BACKGROUND: Fibrinolysis plays an important role in destabilization of atherosclerotic plaques and is tightly regulated by specific inhibitors. OBJECTIVE: The fibrinolysis inhibitors PAI-1 and TAFI were quantified and described in the morphological context of advanced carotid plaques (AHA VI-VIII) to elucidate their role in plaque stability. METHODS: Immunohistochemistry in serial sections along the longitudinal axis of endarterectomies from patients with symptomatic carotid stenosis (n=19) were studied using an antibody specific for free PAI-1 (I205), an antibody with high affinity for TAFI/TAFIa (CP17) and established antibodies for SMC (α-actin), endothelial cells (Von Willebrandt Factor, VWF), macrophages (CD68) and platelets (CD42)...
January 30, 2017: Journal of Thrombosis and Haemostasis: JTH
journal
journal
20181
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"